Eurazeo has successfully closed its Eurazeo Capital V fund (EC-V) with total capital commitments of €3 billion, surpassing its initial target. This achievement underscores strong investor confidence in Eurazeo's mid-large buyout (MLBO) strategy.

The closing of EC-V represents a significant advancement in Eurazeo’s mid-market investment approach, which aims at high-growth companies with global aspirations. The fund focuses on mid-market businesses in Europe and North America, with equity investments ranging from €200 million to €350 million.

EC-V primarily targets three sectors: tech-enabled business services, financial services, and healthcare & life sciences. To date, nearly 50% of the fund's capital has been deployed across six investments. These include Mapal, a Spanish software provider for the food service sector; Eres, a French advisory firm for employee profit-sharing; BMS, an independent specialty insurance broker in the UK and US; Cranial Technologies, a leader in plagiocephaly treatments; Sevetys, a prominent French veterinary clinic group; and Scaled Agile, which specializes in business agility solutions.

The successful fundraising for EC-V builds on the strong performance of its predecessor, Eurazeo Capital IV (EC-IV). The MLBO team at Eurazeo, comprising nearly 30 investment professionals based in Paris, London, Milan, and New York, attracted a diverse array of global investors. These include insurance companies, sovereign wealth funds, pension funds, banks, and family offices.

Overall, the closing of Eurazeo Capital V not only highlights the firm’s robust investment strategy but also reflects a growing interest in mid-market opportunities among institutional investors.